A recent systematic review from Griffith University examines the cost-effectiveness of human papillomavirus (HPV) vaccination programs across Asia Pacific countries, offering valuable lessons for Indonesia’s national immunization strategy.
The study analyzed various HPV vaccine types—bivalent, quadrivalent, and nonavalent—and vaccination strategies, including female-only and gender-neutral approaches. Findings indicate that nonavalent vaccines are more cost-effective in high-income countries (HICs), while bivalent vaccines are more cost-effective in upper-middle-income countries (UMICs). Additionally, gender-neutral vaccination was found to be cost-effective compared to screening alone in all studies conducted.
These insights suggest that Indonesia could enhance its cervical cancer prevention efforts by selecting the most economically viable vaccine type and considering the expansion to gender-neutral vaccination. Tailoring HPV vaccination strategies to the country’s specific economic and demographic context is crucial for maximizing health outcomes and resource utilization
Thumbnail image credit: WHO / Harrison Thane
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.